News | Mammography | June 09, 2020

Volpara Solutions Helps Customers Resume Breast Screening Operations Amid COVID-19

VolparaEnterprise data analysis shows mammography screening volumes are quickly increasing

VolparaEnterprise data analysis shows mammography screening volumes are quickly increasing

June 9, 2020 — More than 75 percent of hospitals and imaging centers that perform mammography across the United States have resumed breast cancer screening operations and exam volumes are recovering rapidly, according to indications from VolparaEnterprise statistical data. The database of over 20 million aggregate, anonymized mammographic images is an invaluable tool for tracking utilization and monitoring image quality across Volpara's global customer base.

Analysis of mammography services during the COVID-19 pandemic shows that as restrictions on non-emergency healthcare services are easing, imaging facilities are expanding their hours and offering weekend appointments to manage the backlog of patients who were unable to attend their regularly scheduled screening dates. Exam volumes in many sites have returned to within 10 percent of pre-pandemic levels. A small group of facilities, about five percent, are recording exam volumes higher than previous levels.

Mammography screening has been strongly impacted by shutdowns related to COVID-19, with estimates placing the downturn in overall outpatient imaging procedures at nearly 70 percent. Volpara is working with customers to help them prepare for increased patient volumes as they resume regular screening operations. During the shutdown, breast centers were able to remotely access VolparaEnterprise to analyze their center's performance data and develop improvement plans prior to resuming screening operations. Technologists also accessed their positioning and compression data, giving them an opportunity to review educational videos to enhance their positioning skills. As facilities reopen, they are using the VolparaEnterprise data and the reporting tools in Aspen Breast to track utilization and prioritize scheduling patients with high breast density and other high-risk factors.

"During this unprecedented time, we know that nothing is as it used to be," said Monica Saini, M.D., MS, Chief Medical Officer, Volpara Solutions. "Facilities that have seen limited scheduling and significant drops in patient volume must now prepare for higher-than-normal volumes to resolve backlog. This includes balancing the need to quickly schedule high-risk patients who missed their regular screenings and operating under new post-COVID physical-distancing norms. Volpara is working hard to offer training and robust data and analytics to help sites recover and offer safe and efficient screening services to their patients."

For more information: www.volparasolutions.com

Related Content

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: National Institute of Allergy and Infectious Diseases, NIH

Novel Coronavirus SARS-CoV-2 Transmission electron micrograph of SARS-CoV-2 virus particles, isolated from a patient. Image captured and color-enhanced at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Image courtesy of  National Institute of Allergy and Infectious Diseases (NIH)

News | Coronavirus (COVID-19) | January 15, 2021
January 15, 2021 — In one of the first studies to examine the impact of the...
A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant the

A, Contrast-enhanced axial T1-weighted fat-saturated image from baseline MRI before initiation of neoadjuvant therapy shows irregular mass (arrow) in upper inner right breast corresponding to biopsy-proven carcinoma. B, Contrast-enhanced axial T1-weighted fat-saturated image from follow-up MRI performed 3 months after initiation of neoadjuvant therapy shows decrease in size of right breast cancer (arrow). C, Contrast-enhanced axial T1-weighted fat-saturated image 3 months after initiation of neoadjuvant therapy shows new mass (arrow) in upper outer left breast that was assessed as BI-RADS 4. Pathologic examination from MRI-guided core biopsy of new suspicious mass revealed benign usual ductal hyperplasia. No atypia or malignancy was identified. Image courtesy of American Roentgen Ray Society (ARRS), American Journal of Roentgenology (AJR)

News | MRI Breast | January 15, 2021
January 15, 2021 — According to ARRS' ...
A targeted intervention providing mammograms to hospitalized Medicaid patients can help patients complete overdue breast cancer screening

Getty Images

News | Mammography | January 14, 2021
January 14, 2021 — Completing cancer screening tests, such as...
DB-I website features new educational tools and streamlined user experience to improve access to medically sourced breast density content
News | Breast Density | January 13, 2021
January 13, 2021 — DenseBreast-info.org (DB-I) invites he
This cutting-edge technology assists radiologists in the interpretation of screening mammograms and allows them to diagnose breast cancer earlier and more accurately
News | Mammography | January 12, 2021
January 12, 2021 — Therapixel announced that...
Myocarditis among recovering COVID-19 athletes less common than previously reported

Getty Images

News | Cardiac Imaging | January 11, 2021
January 11, 2021 — In a letter published in the December issue of the American Heart Association's...
The FDA is monitoring the potential impact of viral mutations, including an emerging variant from the United Kingdom known as the B.1.1.7 variant, on authorized SARS-CoV-2 molecular tests

Getty Images

News | Coronavirus (COVID-19) | January 08, 2021
January 8, 2021 — The U.S.
World-first techniques for predicting breast cancer risk from mammograms that were developed in Melbourne could revolutionise breast screening by allowing it to be tailored to women at minimal extra cost

Getty Images

News | Mammography | January 06, 2021
January 6, 2021 — World-first techniques for predicting breast cancer risk from...
Transaction accelerates Hologic’s entry into oncology growth market, provides new lab capabilities

Getty Images

News | Breast Imaging | January 06, 2021
January 6, 2021 — Hologic, Inc., a global leader in women's...